How long does nivolumab's immune boost last?

Nivolumab (brand name Opdivo) is a “checkpoint‑blocking” antibody that frees T‑cells from the PD‑1 brake so they can hunt cancer cells. Because of that mechanism, the immune boost is not a brief, one‑off flare; it tends to linger for weeks or even months after you finish a dose.

What the numbers look like

How that translates into “lasting” immune activation

1. During treatment – You usually get a dose every 2 or 4 weeks. Between doses the drug concentration is still high enough to keep the PD‑1 pathway shut, so the immune system stays on a higher alert level.

2. After stopping therapy – Because nivolumab binds tightly to PD‑1, the blockade can linger for 3–5 half‑lives (roughly 2–3 months). Even after the drug is gone, the T‑cells that have been activated may remain in the body as memory cells and keep a “memory” of the tumor.

3. Real‑world experience – Many patients who have their cancer in remission after nivolumab go months to years without any recurrence. That’s why we talk about durable responses rather than a short‑term boost.

Key take‑away

• The direct drug effect lasts until the antibody is cleared (a few weeks to a few months).
• The immune memory it creates can keep the system primed for months or years after the last dose.
• There isn’t a precise “X‑weeks” answer—each patient’s biology and tumor type make a difference.

If you’re wondering how this applies to you, your oncologist can look at your individual response and decide whether and when to stop therapy.